ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites

Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC–MS/MS

(2021) Alejandra Martínez-Chávez et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling

(2020) Maria M. Posada et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB

(2020) Qing-Yun Chong et al.   PHARMACOLOGICAL RESEARCH

A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer

(2020) Sara M Tolaney et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib

(2020) Stefanie L. Groenland et al.   CLINICAL PHARMACOKINETICS

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry

(2019) Alejandra Martínez-Chávez et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability

(2019) Alejandra Martínez-Chávez et al.   MOLECULAR PHARMACEUTICS

Breast cancer

(2019) Nadia Harbeck et al.   Nature Reviews Disease Primers

Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood–Brain Barrier of Human Brain and Glioblastoma

(2019) Xun Bao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Blood-brain barrier: An impediment to neuropharmaceuticals

(2015) JT Henderson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib

(2015) Mark C. de Gooijer et al.   INVESTIGATIONAL NEW DRUGS

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS

Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases

(2014) Dominik Gartzke et al.   PHARMACEUTICAL RESEARCH

Investigation of the effect of active efflux at the blood–brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system

(2013) Mari Miyajima et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview

(2012) Alfred H. Schinkel et al.   ADVANCED DRUG DELIVERY REVIEWS

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance

(2012) Karthika Natarajan et al.   BIOCHEMICAL PHARMACOLOGY

Drug Transport across the Blood–Brain Barrier

(2012) William M Pardridge   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

(2012) Laure Elens et al.   PHARMACOGENOMICS

Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Blood−Brain Barrier

(2011) Birk Poller et al.   MOLECULAR PHARMACEUTICS

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

(2010) Yong Zhang et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity

(2009) R. A.B. van Waterschoot et al.   CANCER RESEARCH

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)

(2008) Gergely Szakács et al.   DRUG DISCOVERY TODAY